24 Dec, EOD - Indian

SENSEX 78472.87 (-0.09)

Nifty 50 23727.65 (-0.11)

Nifty Bank 51233 (-0.16)

Nifty IT 43668.9 (-0.36)

Nifty Midcap 100 57057.9 (-0.06)

Nifty Next 50 68857.25 (-0.05)

Nifty Pharma 22558.9 (-0.06)

Nifty Smallcap 100 18732.65 (0.24)

24 Dec, EOD - Global

NIKKEI 225 39336.39 (0.53)

HANG SENG 20098.29 (1.08)

S&P 6112.5 (0.04)

Login/Signup
LOGIN HERE
Cancel

Procter & Gamble Health Ltd

You are Here : Home > Markets > CompanyInformation > Board Meeting
BSE Code : 500126 | NSE Symbol : PGHL | ISIN : INE199A01012 | Industry : Pharmaceuticals |


Board Meeting
Announcement Date Date Of Meeting Purpose Detail
27-Sep-2024 04-Nov-2024 Quarterly Results Procter & Gamble Health Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2024 inter alia to consider and approve We would like to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Monday November 4 2024 inter alia to consider and approve Unaudited Financial Results for the Quarter ended September 30 2024. Find enclosed the unaudited financial results for the quarter ended September 30,2024 along with the limited review report on the same. (As per BSE Announcement Dated on 04/11/2024)
27-Jun-2024 21-Aug-2024 Accounts Procter & Gamble Health Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/08/2024 inter alia to consider and approve In terms of Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we would like to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Wednesday August 21 2024 inter alia to consider and approve Audited Financial Results and Statements for the Financial Year ended June 30 2024 and to consider recommendation of dividend (if any). We are pleased to inform you that the Board at its meeting held today recommended a final dividend of Rs. 60 per equity share for the financial year ended June 30,2024 (As Per BSE Announcement Dated on 21.08.2024)
27-Mar-2024 02-May-2024 Quarterly Results Procter & Gamble Health Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/05/2024 inter alia to consider and approve We would like to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Thursday May 22024 inter alia to consider and approve Unaudited Financial Results for the Quarter ended March 31 2024. Enclosed herewith are the unaudited financial results for the quarter ended March 31,2024 along with the limited review report of the auditors thereon. (As per BSE Announcement Dated on 02/05/2024)
12-Jan-2024 06-Feb-2024 Quarterly Results Procter & Gamble Health Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/02/2024 inter alia to consider and approve In terms of Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we would like to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Tuesday February 6 2024 inter alia to consider and approve unaudited Financial Results for the quarter ended December 31 2023 and to consider declaration of dividend (if any). We are pleased to inform you that at a meeting of the Board of Directors of the Company held today, the Unaudited Financial Results for the quarter ended December 31, 2023 were approved. Further, we are pleased to inform you that the Board of Directors of the Company at its meeting held today, inter alia, have declared an Interim Dividend for the Financial Year 2023-24 of Rs. 200 (including one-time special dividend of Rs. 150) per Equity Share having face value of Rs. 10/- each. The dividend shall be paid on or before March 3, 2024. We are pleased to inform you that at a meeting of Board of Directors held today, the Unaudited Financial results for the quarter ended December 31, 2023 were approved by the Board. Same are enclosed for your perusal, along with Limited review report furnished by the statutory auditors of the Company. Board has approved interim dividend for Financial Year 2023-24 at its meeting held today. Please find enclosed details regarding record date and payout of said dividend. (As Per BSE Announcement Dated on 06/02/2024)
27-Sep-2023 03-Nov-2023 Quarterly Results Procter & Gamble Health Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2023 inter alia to consider and approve We would like to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Friday November 3 2023 inter alia to consider and approve the Unaudited Financial Results for the Quarter ended September 30 2023. We are pleased to inform you that at a meeting of the Board of Directors of the Company held today (commenced at 7:05 pm and ended at 7:44 pm), the Unaudited Financial Results for the quarter ended September 30, 2023 were approved. We are enclosing herewith the following: a. Unaudited Financial Results for the quarter ended September 30, 2023; and b. Limited Review Report in respect of the Unaudited Financial Results for the quarter ended September 30, 2023 furnished by Statutory Auditors of the Company. Kindly take the same on record. Thanking you. Find enclosed unaudited financial results for the quarter ended September 30,2023. (As per BSE Announcement Dated on 03/11/2023)
17-Jul-2023 23-Aug-2023 Accounts Procter & Gamble Health Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/08/2023 inter alia to consider and approve Audited Financial Results and Statements for the Financial Year ended June 30 2023 and recommendation of dividend (if any). Final Dividend & Audited Results (As per BSE Bulletin dated on 17/07/2023) We are pleased to inform you that the Board of Directors of the Company, at its meeting held today recommended a final dividend of Rs. 50 per share for the financial year ended June 30,2023 (As Per BSE Announcement Dated on 14.08.2023) We are pleased to inform you that at the meeting of the Board of Directors of the Company held today (commenced at 7.15 pm and ended at 8:15 pm), the Audited Financial Results for Financial Year ended June 30, 2023 were approved. We are enclosing herewith the following: a. Audited Financial Results for the Financial Year ended June 30, 2023, b. Auditor's Report, in respect of the aforementioned Financial Results, c. A declaration with respect to Audit Report with unmodified opinion We are pleased to further inform you that the Board of Directors of the Company at its meeting held today, inter alia, have recommended a final dividend of Rs. 50 per equity share, for the financial year ended June 30, 2023. The dividend shall be paid between November 28, 2023 to December 18, 2023, on approval of the Members at the 56th Annual General Meeting. We are pleased to inform you that the Board of Directors of the Company, at its meeting held today recommended a final dividend of Rs. 50 per share for the financial year ended June 30,2023 (As Per BSE Announcement dated on 23.08.2023)
24-Apr-2023 15-May-2023 Quarterly Results Procter & Gamble Health Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 15/05/2023 inter alia to consider and approve In terms of Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we wish to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Monday May 152023 inter alia to consider and approve the unaudited financial results for the quarter ended March 312023. We are pleased to inform you that at the meeting of the Board of Directors of the Company held today (started at 6:50 p.m. and concluded at 8:00 p.m.), the Unaudited Financial Results for the quarter ended March 31, 2023 were approved. We are enclosing herewith the following: a. Unaudited Financial Results for the quarter ended March 31, 2023; b. Limited Review Report in respect of the Unaudited Financial Results for the quarter ended March 31, 2023 furnished by Statutory Auditors of the Company Kindly take the same on record and oblige. We are pleased to inform you that at the meeting of the Board of Directors of the Company held today (started at 6:50 p.m. and concluded at 8:00 p.m.), the Unaudited Financial Results for the quarter ended March 31, 2023 were approved. We are enclosing herewith the following: a. Unaudited Financial Results for the quarter ended March 31, 2023; b. Limited Review Report in respect of the Unaudited Financial Results for the quarter ended March 31, 2023 furnished by Statutory Auditors of the Company (As Per BSE Announcement dated on 15.05.2023)
17-Mar-2023 17-Mar-2023 Change in Directors It is informed that pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors of the Company, at its meeting held today, have appointed Ms. Seema Sambasivan as an Additional (Non- Executive) Director of the Company with effect April 1, 2023, subject to allotment of Director Identification Number by the Ministry of Corporate Affairs. Ms. Sambasivan will hold office as Additional Director up to the ensuing Annual General Meeting. Brief Profile of Ms. Seema Sambasivan is enclosed. Kindly take the same on record and oblige. Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors of the Company, at its meeting held today, have appointed Mr. Lokesh Chandak as Additional (Executive) Director of the Company effective April 1, 2023. His appointment as Director is subject to allotment of Director Identification Number by the Ministry of Corporate Affairs. Mr. Chandak will hold office as Additional Director up to the ensuing Annual General Meeting. Appointment of Mr. Chandak as Executive Director is also subject to approval of the Shareholders of the Company. A brief profile of Mr. Chandak is enclosed for your kind perusal. Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors of the Company, at its meeting held today, have appointed Mr. Lokesh Chandak as Chief Financial Officer effective April 1, 2023. A brief profile of Mr. Chandak is enclosed for your kind perusal. Kindly take the same on record and oblige. (As Per BSE Announcement Dated on 17.03.2023)
09-Jan-2023 05-Feb-2023 Quarterly Results Procter & Gamble Health Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/02/2023 inter alia to consider and approve In terms of Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we wish to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Wednesday February 8 2023 inter alia to consider and approve the unaudited financial results for the quarter ended December 312022 and the declaration of interim dividend for the Financial Year 2022-23 if any. Kindly take the same on record. Procter & Gamble Health Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/02/2023 ,inter alia, to consider and approve With reference to the announcement dated January 09,2023 and in terms of Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we wish to inform you that a meeting of the Board of Directors of the Company is now rescheduled to be held on Sunday, February 5, 2023, inter alia, to consider and approve the unaudited financial results for the quarter ended December 31,2022. We would like to further inform you that the Board at the said meeting, would also consider the declaration of interim dividend for the Financial Year 2022-23. The record date for payment of the Interim dividend, if declared at the Board meeting, will be Monday, February 13, 2023. With reference to the announcement dated January 09,2023 and in terms of Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we wish to inform you that a meeting of the Board of Directors of the Company is now rescheduled to be held on Sunday, February 5, 2023, inter alia, to consider and approve the unaudited financial results for the quarter ended December 31,2022. We would like to further inform you that the Board at the said meeting, would also consider the declaration of interim dividend for the Financial Year 2022-23. The record date for payment of the Interim dividend, if declared at the Board meeting, will be Monday, February 13, 2023. (As per BSE Announcement Dated on 16/01/2023) We are pleased to inform you that at the meeting of the Board of Directors of the Company held today (commenced at 12:04 p.m. and ended at 12:48 p.m.), the Unaudited Financial Results for the quarter ended December 31, 2022 were approved. We are enclosing herewith the following: a. Unaudited Financial Results for the quarter ended December 31, 2022; b. Press Release; and c. Limited Review Report in respect of the Unaudited Financial Results for the quarter ended December 31, 2022 furnished by Statutory Auditors of the Company. Further, we are pleased to inform you that the Board of Directors of the Company at its meeting held today, inter alia, have recommended an Interim Dividend for the Financial Year 2022-23 of Rs. 45 per Equity Share (Face Value of Rs. 10/- each). The dividend shall be paid on or before March 05, 2023, record date for the purpose of eligibility for payment of said Interim Dividend shall be February 13,2023. we are pleased to inform you that the Board of Directors of the Company at its meeting held today, inter alia, have recommended an Interim Dividend for the Financial Year 2022-23 of Rs. 45 per Equity Share (Face Value of Rs. 10/- each). The dividend shall be paid on or before March 05, 2023. As informed earlier in our letter dated January 16,2023, record date for the purpose of eligibility for payment of said Interim Dividend shall be February 13,2023. (As Per BSE Announcement Dated on 05.02.2023) Further to communication dated February 05,2023, we would like to inform you that the Board of Directors of the Company, at its meeting held yesterday, have approved re- appointment of Mr. Milind Thatte as Managing Director of the Company for a further period of five years effective April 01, 2023, subject to approval of shareholders of the Company. Mr. Milind Thatte is not debarred from holding the office of Director by virtue of any order from SEBI/MCA or any other such authority and he does not hold any shares in the Company and is not related to any of the Directors of the Company. Kindly take the same on record and oblige. (As Per BSE Announcement Dated on 06.02.2023) Board of Directors of the Company at its Meeting held on February 05, 2023, have declared an Interim dividend of Rs. 45 per equity share of face value of Rs. 10 each for Company's Financial Year 2022-23. In accordance with the provisions of the Income Tax Act, 1961 as amended by and read with the provisions of the Indian Finance Act, 2020, dividend declared and paid by the Company after April 1, 2020, is taxable in the hands of shareholders and the Company is required to deduct the tax at source ('TDS') on the distribution of dividend income to its shareholders at the applicable rates. Accordingly, shareholders are requested to furnish requisite details to enable the Company to determine the appropriate TDS rate (if any). (As Per BSE Announcement Dated on 07/02/2023)
07-Oct-2022 11-Nov-2022 Quarterly Results Procter & Gamble Health Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/11/2022 inter alia to consider and approve the unaudited financial results for the quarter ended September 30 2022. The Board Meeting to be held on 09/11/2022 has been revised to 11/11/2022 With reference to the announcement dated October 7, 2022 and in terms of Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we wish to inform you that the meeting of the Board of Directors of the Company is now rescheduled to be held on Friday, November 11, 2022, inter alia, to consider and approve the unaudited financial results for the quarter ended September 30, 2022 (As Per BSE Announcement Dated on 17.10.2022) We are pleased to inform you that at the meeting of the Board of Directors of the Company held today (started at 6.25 p.m. and concluded at 7.15p.m.), the Unaudited Financial Results for the quarter ended September 30, 2022 were approved. We are enclosing herewith the following: a. Unaudited Financial Results for the quarter ended September 30, 2022; b. Press Release; and c. Limited Review Report in respect of the Unaudited Financial Results for the quarter ended September 30, 2022 furnished by Statutory Auditors of the Company Kindly take the same on record and oblige. (As Per BSE Announcement dated on 11.11.2022)
05-Aug-2022 29-Aug-2022 Accounts Procter & Gamble Health Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/08/2022 inter alia to consider and approve In terms of Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we would like to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Monday August 292022 inter alia to consider and approve Audited Financial Results and Statements for the Financial Year ended June 30 2022 and to consider recommendation of dividend (if any). We are pleased to further inform you that the Board of Directors of the Company at its meeting held today, inter alia, have recommended a final dividend of Rs.11.50 per equity share, for the financial year ended June 30, 2022. The dividend shall be paid between November 28, 2022 to December 18, 2022, on approval of the Members at the 55th Annual General Meeting. We are pleased to inform you that at the meeting of the Board of Directors of the Company held today (commenced at 12.45 pm and ended at 2:55 pm), the Audited Financial Results for Financial Year ended June 30, 2022 were approved. We are enclosing herewith the following: Audited Financial Results for the Financial Year ended June 30, 2022, as per format prescribed under Regulation 33 of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015; Auditor's Report, in respect of the aforementioned Financial Results, as furnished by the Statutory Auditors of the Company; Press Release; and declaration with respect to Audit Report with unmodified opinion to the aforementioned Audited Financial Results We are pleased to further inform you that the Board of Directors of the Company at its meeting held today, inter alia, have recommended a final dividend of Rs.11.50 per equity share, for the financial year ended June 30, 2022. We would like to inform that, we had inadvertently missed attaching cash flow statement while uploading our financial results for the year ended June 30, 2022, approved by the Board at its meeting held today. Request you to kindly note that, initial submission made with the exchange, was made within the prescribed timeline and this is only a revision to the same, due to an inadvertent error as described above. We are hereby re-uploading a full set of results, for your perusal. (As Per BSE Announcement Dated on 29.08.2022) We wish to inform you that the Board of Directors of the Company at their meeting held on August 29, 2022 have approved shifting the registered office address of the Company from 'Godrej One, 8th Floor, Pirojshanagar, Eastern Express Highway, Vikhroli East Mumbai 400 079' to 'P&G Plaza, Cardinal Gracias Road, Chakala, Andheri (E), Mumbai - 400099' w.e.f. January 1, 2023. This is for your information and records. (As Per BSE Announcement dated on 14.09.2022)
30-Mar-2022 05-May-2022 Quarterly Results Procter & Gamble Health Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/05/2022 inter alia to consider and approve In terms of Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we wish to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Thursday May 05 2022 inter alia to consider and approve the unaudited financial results for the quarter ended March 31 2022 Kindly take the same on record. Procter & Gamble Health Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/05/2022 ,inter alia, to consider and approve We refer to our letter dated March 30, 2022, informing that a meeting of the Board of Directors of the Company is scheduled to be held on Thursday, May 5, 2022, to consider and approve Unaudited Financial Results for the quarter ended March 31, 2022. We would like to further inform you that the Board at the said meeting, would also consider declaration of interim dividend for the Financial Year 2021-22. The record date for payment of the Interim dividend, if declared at the Board meeting, will be Friday, May 13, 2022. Kindly take the same on record. (As Per BSE Announcement dated on 28.04.2022) We are pleased to inform you that at the meeting of the Board of Directors of the Company held today (commenced at 6:00 p.m. and ended at 7: 20 p.m.), the Unaudited Financial Results for the quarter ended March 31,2022 were approved. We are enclosing herewith the following: a. Unaudited Financial Results for the quarter ended March 31, 2022; b. Press Release; and c. Limited Review Report in respect of the Unaudited Financial Results for the quarter ended March 31, 2022 furnished by Statutory Auditors of the Company Further, we are pleased to inform you that the Board of Directors of the Company at its meeting held today, inter alia, have recommended an Interim Dividend for the Financial Year 2021-22 of Rs. 41 per Equity Share (Face Value of Rs. 10/- each). The dividend shall be paid on or before May 31, 2022. (As Per BSE Announcement Dated on 05/05/2022)
17-Jan-2022 09-Feb-2022 Quarterly Results Procter & Gamble Health Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/02/2022 inter alia to consider and approve In terms of Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we wish to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Wednesday February 9 2022 inter alia to consider and approve the unaudited financial results for the quarter ended December 31 2021. We are pleased to inform you that at the meeting of the Board of Directors of the Company held today, the Unaudited Financial Results for the quarter ended December 31, 2021 were approved. We are enclosing herewith the following: a. Unaudited Financial Results for the quarter ended December 31, 2021; b. Press Release; and c. Limited Review Report in respect of the Unaudited Financial Results for the quarter ended December 31, 2021 furnished by Statutory Auditors of the Company Kindly take the same on record and oblige. (As per BSE Announcement Dated on 09/02/2022)
08-Oct-2021 09-Nov-2021 Quarterly Results Quarterly Results We are pleased to inform you that at the meeting of the Board of Directors of the Company held today, the Unaudited Financial Results for the quarter ended September 30, 2021 were approved. We are enclosing herewith the following: a. Unaudited Financial Results for the quarter ended September 30, 2021; b. Press Release; and c. Limited Review Report in respect of the Unaudited Financial Results for the quarter ended September 30, 2021 furnished by Statutory Auditors of the Company Kindly take the same on record and oblige. (As Per BSE Announcement dated on 09.11.2021)
16-Aug-2021 26-Aug-2021 Accounts Procter & Gamble Health Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/08/2021 inter alia to consider and approve We would like to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Thursday August 262021 inter alia to consider and approve Audited Financial Results and Statements for the Financial Year ended June 30 2021 and to consider recommendation of dividend (if any). We inform you that the Board of Directors of the Company at its meeting held today, inter alia, have recommended a final dividend of Rs. 130 per equity share, for the financial year ended June 30, 2021, which includes a one-time special dividend of Rs. 90 per equity share. Kindly take the same on record. (As Per BSE Announcement Dated on 26.08.2021) We inform you that the Board of Directors of the Company at its meeting held today inter alia have recommended a final dividend of Rs. 130 per equity share for the financial year ended June 30 2021 which includes a one-time special dividend of Rs. 90 per equity share. Kindly take the same on record. (As Per BSE Announcement Dated on 8/26/2021 7:28:10 AM) We inform you that the Board of Directors of the Company at its meeting held today inter alia have recommended a final dividend of Rs. 130 per equity share for the financial year ended June 30 2021 which includes a one-time special dividend of Rs. 90 per equity share. Kindly take the same on record. (As Per BSE Announcement Dated on 8/26/2021 7:28:10 AM)
1 2